Tech Company Financing Transactions
Selexys Pharmaceuticals Funding Round
Selexys Pharmaceuticals closed a $23 million Series A venture capital round on 9/19/2012. Investors included MPM Capital and private investors.
Transaction Overview
Company Name
Announced On
9/19/2012
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
MPM Capital (Lead Investor) (Todd Foley)
Proceeds Purpose
The combination of the Novartis agreement and the closing of the Series A financing will allow Selexys to advance the SelG1 program through a large Phase 2 clinical study in sickle cell patients and will also fund a second program at Selexys, an anti-PSGL-1 antibody, through a Phase I clinical study.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
840 Research Parkway 510
Oklahoma City, OK 73104
USA
Oklahoma City, OK 73104
USA
Phone
Website
Email Address
Overview
Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that is developing drugs to treat inflammatory and thrombotic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Rollins
Chief Medical Officer
Rodger McEver
Chief Scientific Officer
Richard Cummings
VP - Bus. Development
David Falconer
VP - Operations
Richard Alvarez
Browse more venture capital transactions:
Prev: 9/19/2012: Familiar venture capital transaction
Next: 9/19/2012: Xcovery Vision venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs